Edition:
United States

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

32.42USD
20 Oct 2017
Change (% chg)

$-0.40 (-1.22%)
Prev Close
$32.82
Open
$32.79
Day's High
$32.87
Day's Low
$31.95
Volume
271,230
Avg. Vol
620,204
52-wk High
$68.12
52-wk Low
$31.57

Latest Key Developments (Source: Significant Developments)

Mallinckrodt says ‍four product launches expected over next three years​
Wednesday, 4 Oct 2017 07:00am EDT 

Oct 4 (Reuters) - Mallinckrodt Plc : :Mallinckrodt Plc discusses pipeline transformation, company outlook at investor briefing.Mallinckrodt Plc says ‍four product launches expected over next three years​.Mallinckrodt Plc - aggregate net sales expectations for near-term development programs, sum of which is expected to exceed $675 million at peak.Mallinckrodt Plc says ‍total pipeline expected to exceed net sales of $1 billion at peak​.Mallinckrodt Plc says ‍pipeline expected to contribute over 20 percent of total growth long term​.  Full Article

Mallinckrodt licenses inhaled xenon gas therapy development product
Monday, 2 Oct 2017 06:45am EDT 

Oct 2 (Reuters) - Mallinckrodt Plc :Mallinckrodt Plc says ‍under terms of agreement, later today Mallinckrodt will pay $10 million upfront with cash on hand​.Mallinckrodt - anticipates dilution of $0.10 to $0.15 to adjusted diluted earnings per share for rest of 2017, modestly lower in 2018 from deal​.Mallinckrodt Plc says ‍will make additional payments of up to $25 million dependent on achievement of clinical, regulatory and sales milestones​.Mallinckrodt Plc - ‍FDA Special Protocol Assessment approved for Phase 3 trial to begin early 2018​.Mallinckrodt - ‍NeuroproteXeon to get upfront payment of $10 million in cash on hand from co, with potential additional payments of up to $25 million​.  Full Article

Mallinckrodt Q2 sales $824.5 million
Tuesday, 8 Aug 2017 06:00am EDT 

Aug 8 (Reuters) - Mallinckrodt Plc :Mallinckrodt Plc reports earnings results for second quarter of fiscal 2017.Reaffirms FY 2017 adjusted earnings per share view $7.40 to $8.00.Q2 sales $824.5 million.Q2 gaap earnings per share $0.72 from continuing operations.Mallinckrodt Plc - ‍adjusted diluted earnings per share guidance reiterated at $7.40 to $8.00 for fiscal 2017​.  Full Article

Mallinckrodt to acquire Infacare Pharmaceutical, Stannsoporfin
Friday, 4 Aug 2017 07:00am EDT 

Aug 4 (Reuters) - Mallinckrodt Plc :Mallinckrodt to acquire Infacare Pharmaceutical Corporation and Stannsoporfin, its proprietary therapy in late-stage development for treatment of newborns at risk for developing severe jaundice.Mallinckrodt PLC - ‍financial terms of transaction include an upfront payment of $80 million​.Mallinckrodt PLC - ‍expects dilution from acquisition to adjusted diluted earnings per share of $0.15 to $0.20 in 2017; dilution modestly higher in 2018​.Mallinckrodt PLC - ‍financial terms of transaction include additional payments of up to $345 million dependent on regulatory and sales milestones​.Mallinckrodt PLC - ‍if approved, Mallinckrodt expects Stannsoporfin to be commercialized by company's existing sales organization​.  Full Article

Mallinckrodt enrolls first patient in Phase 4 registry of Inomax gas for inhalation for pulmonary hypertension in neonates
Tuesday, 1 Aug 2017 07:45am EDT 

Aug 1 (Reuters) - Mallinckrodt Plc :Mallinckrodt enrolls first patient in Phase 4 registry of Inomax® (nitric oxide) gas for inhalation for pulmonary hypertension in neonates.Mallinckrodt Plc - estimated enrollment for study is 168 patients, with completion expected by 2022.  Full Article

U.S. FDA designates Mallinckrodt's StrataGraft as Regenerative Medicine Advanced Therapy
Tuesday, 18 Jul 2017 07:00am EDT 

July 18 (Reuters) - Mallinckrodt Plc :Mallinckrodt- investigational, tissue-based therapy StrataGraft currently under evaluation in a Phase 3 trial.  Full Article

Mallinckrodt phase 3 Terlipressin trial achieves enrollment target ahead of schedule
Thursday, 13 Jul 2017 04:45pm EDT 

July 13 (Reuters) - Mallinckrodt Plc ::Mallinckrodt phase 3 Terlipressin trial achieves its enrollment target ahead of schedule.  Full Article

Mallinckrodt says FDA grants orphan drug designation to co's development product for duchenne muscular dystrophy
Wednesday, 12 Jul 2017 04:45pm EDT 

July 12 (Reuters) - Mallinckrodt Plc :FDA grants orphan drug designation to Mallinckrodt development product for potential treatment of duchenne muscular dystrophy.Mallinckrodt Plc - phase 2 trial should begin later this year.  Full Article

Mallinckrodt finalizes agreement with DEA and USAOS
Tuesday, 11 Jul 2017 03:07pm EDT 

July 11 (Reuters) - Mallinckrodt Plc :Mallinckrodt finalizes previously announced agreement with DEA and USAOS.Confirmed that it has finalized agreement reached with U.S. Drug Enforcement Administration and U.S. Attorneys' Offices.Will pay $35 million to resolve all potential claims as part of agreement.Settlement contains no admission of liability for civil penalties for relevant conduct.Finalized agreement will have no material adverse effect on company's financial condition, results of operations or cash flows.Finalized agreement reached with U.S. DEA, USAOS to settle previously disclosed investigations on co's suspicious order monitoring program among other things ​.  Full Article

Mallinckrodt enrolls first patient in Phase 2B trial of H.P. acthar gel
Wednesday, 14 Jun 2017 04:30pm EDT 

June 14 (Reuters) - Mallinckrodt Plc :Mallinckrodt enrolls first patient in Phase 2B trial of H.P. Acthar® gel (repository corticotropin injection) for amyotrophic lateral sclerosis (ALS).  Full Article

BRIEF-Mallinckrodt to conduct Phase 4 trial of H.P. Acthar Gel

* Mallinckrodt will conduct Phase 4 trial of H.P. Acthar® Gel (repository corticotropin injection) for symptomatic sarcoidosis